TapewireFind a company

person · Reporting owner

Invus Advisors, L.L.C.

Disclosed activity across 2 companies

Tapewire entity
91092
SEC CIK
0001404553

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970Director · 10% ownerMay 10, 2024May 14, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnotes136,180,481 Reported balance After 2024-05-10 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2024-05-10 · Exercise / conversion · Acquired 57,546,100 · Balance 136,180,481

F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2: These securities are directly held by Artal International S.C.A.

F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes3,516,214 Reported balance Holding disclosure · report date 2024-05-10 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 3,516,214

F3: These securities are directly held by Invus Public Equities, L.P.

F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnotes35,402,689 Reported balance Holding disclosure · report date 2024-05-10 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 35,402,689

F4: These securities are directly held by Invus, L.P.

F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Series A Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnotes1,150,922 Reported balance After 2024-05-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2024-05-10 · Grant · Acquired 1,150,922 · Balance 1,150,922

F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2: These securities are directly held by Artal International S.C.A.

F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Series A Convertible Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnotes0 Reported balance After 2024-05-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-05-10 · Exercise / conversion · Disposed 1,150,922 · Balance 0

F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2: These securities are directly held by Artal International S.C.A.

F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2: These securities are directly held by Artal International S.C.A.

F3: These securities are directly held by Invus Public Equities, L.P.

F4: These securities are directly held by Invus, L.P.

F5: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2018-04-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-04-24 · Disposition to issuer · Disposed 87,460,875 · Balance 0

F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.

F3: These securities are directly held by Invus, L.P.

F4: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.

F3: These securities are directly held by Invus, L.P.

F4: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 10, 2024 Filed May 14, 2024 21:17 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionSeries A Convertible Preferred Stock · Derivative 1,150,922 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-059789 · ownership.xml · derivative · entry 5

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock · 57,546,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · kind: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · derivative.exercise_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · derivative.expiration_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
May 10, 2024 Filed May 14, 2024 21:17 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantSeries A Convertible Preferred Stock · Derivative 1,150,922 $108.50 $124,875,037.00
Disclosure

SEC source: 0000950170-24-059789 · ownership.xml · derivative · entry 4

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,150,922

Underlying: Common Stock · 57,546,100 shares

Expires not disclosed

F1 · derivative.exercise_price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · kind: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · derivative.exercise_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · derivative.expiration_date: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
May 10, 2024 Filed May 14, 2024 21:17 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 57,546,100 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-059789 · ownership.xml · nonDerivative · entry 1

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 136,180,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F1 · price: On March 13, 2024, Artal International S.C.A. acquired 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share. Each share of Preferred Stock would automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions (the "Conditions"); however, absent the satisfaction of such conditions, the shares were not convertible and as such, the Preferred Stock was originally reported on Table I. On May 10, 2024, all Conditions were met, and the 1,150,922 shares of Preferred Stock became derivative securities and automatically converted into 57,546,100 shares of Issuer Common Stock.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
March 13, 2024 Filed Mar 14, 2024 01:22 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantSeries A Convertible Preferred Stock 1,150,922 $108.50 $124,875,037.00
Disclosure

SEC source: 0000950170-24-031072 · ownership.xml · nonDerivative · entry 1

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,150,922

F1 · kind: On March 11, 2024, Artal International S.C.A. entered into a purchase agreement (the "Purchase Agreement") with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 1,150,922 shares of Series A convertible preferred stock, $0.01 par value per share (the "Preferred Stock") of the Issuer at a price of $108.50 per share (the "Purchase Price"). Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock") upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on March 13, 2024.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F3 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 05, 2023 Filed Jun 5, 2023 20:46 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 27,775,050 $2.60 $72,215,130.00
Disclosure

SEC source: 0000899243-23-014464 · doc4.xml · nonDerivative · entry 1

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 78,634,381

F1 · kind: On May 31, 2023, Artal International S.C.A. entered into a purchase agreement (the "Purchase Agreement") with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 24,152,218 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), of the Issuer at a price of $2.60 per share (the "Purchase Price"). The Purchase Agreement also provided Artal International S.C.A. the right to purchase from the Issuer, on a pro rata basis, up to an additional 3,622,832 shares of Issuer Common Stock at a price per share equal to the Purchase Price. On June 1, 2023, pursuant to the 2023 Purchase Agreement, Artal International S.C.A. exercised its right to purchase an additional 3,622,832 shares of Issuer Common Stock at a price per share equal to the Purchase Price. The purchase closed on June 5, 2023.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
August 05, 2022 Filed Aug 9, 2022 20:46 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 2,426,070 $2.50 $6,065,175.00
Disclosure

SEC source: 0000899243-22-028108 · doc4.xml · nonDerivative · entry 1

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 50,859,331

F1 · kind: Pursuant to a purchase agreement dated July 27, 2022, between Artal International S.C.A. and the Issuer, on August 5, 2022, Artal International S.C.A. purchased an additional 2,426,070 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
August 01, 2022 Filed Aug 1, 2022 20:15 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 16,173,800 $2.50 $40,434,500.00
Disclosure

SEC source: 0000899243-22-027156 · doc4.xml · nonDerivative · entry 1

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Wittouck Amaury · CIK 0001841311 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 48,433,261

F1 · kind: On July 27, 2022, Artal International S.C.A. entered into a purchase agreement with the Issuer pursuant to which Artal International S.C.A. agreed to purchase 16,173,800 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. The Geneva branch of Artal International S.C.A. is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
December 16, 2020 Filed Dec 17, 2020 19:39 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 10,937,500 $3.20 $35,000,000.00
Disclosure

SEC source: 0000899243-20-034268 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal Treasury Ltd · CIK 0001766952 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 32,259,461

F1 · kind: On December 11, 2020, Artal International S.C.A. entered into a subscription agreement with the Issuer and other parties thereto, pursuant to which Artal International S.C.A. agreed to purchase 10,937,500 shares of Class A common stock of the Issuer at a price of $3.20 per share. The purchase closed on December 16, 2020.

F2 · ownership.nature: These securities are directly held by Artal International S.C.A.

F5 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal Treasury Limited is the managing member of Invus Public Equities Advisors, LLC. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. and, through its Geneva branch, is the sole stockholder of Artal Treasury Limited. The managing partner of Artal International S.C.A. is Artal International Management S.A. The parent company of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F6 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

F7 · ownership.nature: Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 4.

Read SEC document
June 28, 2018 Filed Jun 29, 2018 20:23 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 57,724 $12.45 $718,935.10
Disclosure

SEC source: 0000899243-18-018727 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,516,214

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 27, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.40 to $12.60 per share and the shares reported as purchased on June 28, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.22 to $12.76 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 27, 2018 Filed Jun 29, 2018 20:23 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 125,114 $12.54 $1,568,441.62
Disclosure

SEC source: 0000899243-18-018727 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,458,490

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 27, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.40 to $12.60 per share and the shares reported as purchased on June 28, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.22 to $12.76 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 25, 2018 Filed Jun 26, 2018 21:32 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 228,264 $12.95 $2,955,082.92
Disclosure

SEC source: 0000899243-18-018161 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,333,376

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 22, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.14 to $13.49 per share and the shares reported as purchased on June 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.57 to $13.08 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 22, 2018 Filed Jun 26, 2018 21:32 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 25,461 $13.36 $340,090.22
Disclosure

SEC source: 0000899243-18-018161 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,105,112

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 22, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.14 to $13.49 per share and the shares reported as purchased on June 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.57 to $13.08 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 21, 2018 Filed Jun 21, 2018 21:55 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 51,600 $13.27 $684,613.32
Disclosure

SEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,079,651

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 20, 2018 Filed Jun 21, 2018 21:55 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 12,391 $13.28 $164,613.20
Disclosure

SEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,028,051

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 19, 2018 Filed Jun 21, 2018 21:55 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 8,982 $13.45 $120,818.68
Disclosure

SEC source: 0000899243-18-017617 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,015,660

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 19, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.38 to $13.50 per share, the shares reported as purchased on June 20, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.22 to $13.30 per share, and the shares reported as purchased on June 21, 2018 were purchased in multiple transactions at actual purchase prices ranging from $13.12 to $13.52 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 18, 2018 Filed Jun 18, 2018 22:56 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 36,584 $13.06 $477,937.03
Disclosure

SEC source: 0000899243-18-017071 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,006,678

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 14, 2018 Filed Jun 18, 2018 22:56 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 9,200 $12.66 $116,461.88
Disclosure

SEC source: 0000899243-18-017071 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,970,094

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 14, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.575 to $12.79 per share and the shares reported as purchased on June 18, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.95 to $13.10 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 12, 2018 Filed Jun 12, 2018 22:10 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 107,023 $12.83 $1,373,244.22
Disclosure

SEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,960,894

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 11, 2018 Filed Jun 12, 2018 22:10 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 98,626 $12.75 $1,257,451.91
Disclosure

SEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,853,871

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 08, 2018 Filed Jun 12, 2018 22:10 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 29,747 $12.89 $383,426.93
Disclosure

SEC source: 0000899243-18-016245 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,755,245

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 8, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $13.03 per share, the shares reported as purchased on June 11, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.60 to $12.99 per share, and the shares reported as purchased on June 12, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.63 to $12.95 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 07, 2018 Filed Jun 7, 2018 23:37 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 57,439 $12.93 $742,508.21
Disclosure

SEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,725,498

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 06, 2018 Filed Jun 7, 2018 23:37 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 95,079 $12.58 $1,196,369.55
Disclosure

SEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,668,059

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 05, 2018 Filed Jun 7, 2018 23:37 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 173,121 $12.45 $2,156,187.43
Disclosure

SEC source: 0000899243-18-015606 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,572,980

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on June 5, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.10 to $12.73 per share, the shares reported as purchased on June 6, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.32 to $12.76 per share, and the shares reported as purchased on June 7, 2018 were purchased in multiple transactions at actual purchase prices ranging from $12.61 to $13.06 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 04, 2018 Filed Jun 4, 2018 21:31 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 121,803 $12.24 $1,490,576.39
Disclosure

SEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,399,859

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
June 01, 2018 Filed Jun 4, 2018 21:31 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 147,339 $12.22 $1,800,040.56
Disclosure

SEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,278,056

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
May 31, 2018 Filed Jun 4, 2018 21:31 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 147,339 $11.62 $1,712,049.71
Disclosure

SEC source: 0000899243-18-014948 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,130,717

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on May 31, 2018 were purchased in multiple transactions at actual purchase prices ranging from $10.59 to $12.00 per share, the shares reported as purchased on June 1, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.50 to $12.62 per share, and the shares reported as purchased on June 4, 2018 were purchased in multiple transactions at actual purchase prices ranging from $11.82 to $12.39 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
May 30, 2018 Filed May 31, 2018 00:53 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 147,339 $10.32 $1,521,024.70
Disclosure

SEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,983,378

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
May 29, 2018 Filed May 31, 2018 00:53 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 147,339 $9.84 $1,450,419.85
Disclosure

SEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,836,039

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
May 25, 2018 Filed May 31, 2018 00:53 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 138,700 $9.62 $1,334,973.63
Disclosure

SEC source: 0000899243-18-014494 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,688,700

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on May 25, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.37 to $9.73 per share, the shares reported as purchased on May 29, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.45 to $10.01 per share, and the shares reported as purchased on May 30, 2018 were purchased in multiple transactions at actual purchase prices ranging from $9.82 to $10.61 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
April 24, 2018 Filed Apr 24, 2018 21:03 UTC Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 Disposition to issuerCommon Stock 87,460,875 $40.00 $3,498,435,000.00
Disclosure

SEC source: 0000899243-18-010670 · doc4.xml · nonDerivative · entry 1

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2 · price: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.

F3 · ownership.direct: These securities are directly held by Invus, L.P.

F4 · ownership.direct: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F5 · ownership.direct: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document
November 17, 2017 Filed Nov 18, 2017 01:09 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 50,000 $9.85 $492,500.00
Disclosure

SEC source: 0000899243-17-026881 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,550,000

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
November 15, 2017 Filed Nov 18, 2017 01:09 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 130,727 $10.21 $1,334,395.85
Disclosure

SEC source: 0000899243-17-026881 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,500,000

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on November 15, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.75 to $10.49 per share. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
November 14, 2017 Filed Nov 15, 2017 00:32 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 215,133 $9.47 $2,037,847.34
Disclosure

SEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,369,273

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
November 13, 2017 Filed Nov 15, 2017 00:32 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 215,133 $9.75 $2,097,933.99
Disclosure

SEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,154,140

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
November 10, 2017 Filed Nov 15, 2017 00:32 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 PurchaseCommon Stock 145,680 $9.74 $1,418,384.18
Disclosure

SEC source: 0000899243-17-026246 · doc4.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 939,007

F1 · kind: The purchases were made in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: The shares reported as purchased on November 10, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.12 to $9.98 per share, the shares reported as purchased on November 13, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.50 to $9.83 per share, and the shares reported as purchased on November 14, 2017 were purchased in multiple transactions at actual purchase prices ranging from $9.23 to $9.68 per share, in each case exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F3 · ownership.nature: These securities are directly held by Invus Public Equities, L.P.

F6 · ownership.nature: Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of each of Invus Public Equities Advisors, LLC and Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., both of which are wholly owned subsidiaries of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend (the "Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F7 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Read SEC document
September 16, 2016 Filed Sep 16, 2016 22:29 UTC Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 SaleCommon Stock 12,512,124 $24.83 $310,642,256.19
Disclosure

SEC source: 0000899243-16-029167 · doc4.xml · nonDerivative · entry 1

Invus, L.P. · CIK 0001404570 · Director · 10% owner

Artal International S.C.A. · CIK 0001218180 · Director · 10% owner

Artal International Management S.A. · CIK 0001522131 · Director · 10% owner

Artal Group S.A. · CIK 0001053906 · Director · 10% owner

Westend S.A. · CIK 0001283968 · Director · 10% owner

Stichting Administratiekantoor Westend · CIK 0001460840 · Director · 10% owner

Minne Pascal · CIK 0001460839 · Director · 10% owner

Invus Advisors, L.L.C. · CIK 0001404553 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,460,875

F1 · price: This amount represents the $24.8273 sales price per share of common stock of the Issuer received by Invus, L.P. in connection with a secondary block trade which closed on September 16, 2016.

F2 · ownership.direct: These securities are directly held by Invus, L.P.

F3 · ownership.direct: Invus Advisors, L.L.C. is the general partner of Invus, L.P. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. The managing partner of Artal International S.C.A. is Artal International Management S.A., which is a wholly owned subsidiary of Artal Group S.A., which is a wholly owned subsidiary of Westend S.A., which is a wholly owned subsidiary of Stichting Administratiekantoor Westend ("Stichting"). Mr. Pascal Minne is the sole member of the board of the Stichting.

F4 · ownership.direct: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.